Apixaban for treatment of embolic stroke of undetermined source (ATTICUS randomized trial) - Rationale and study design Tobias Geisler

Apixaban for treatment of embolic stroke of undetermined source (ATTICUS randomized trial) - Rationale and study design Tobias Geisler Reviewed by Carmen Lahiff-Jenkins on Monday, February 13, 2017 Rating: 5

2 comments:

  1. Apixaban (INN, trade name Eliquis) is an anticoagulant for the prevention of venous thromboembolism and the prevention of stroke in atrial fibrillation. It is a direct factor Xa inhibitor. Apixaban has been available in Europe since May 2011. The drug was developed in a joint venture by Pfizer and Bristol-Myers Squibb. Apixaban

    ReplyDelete
  2. Apixaban (INN, trade name Eliquis) is an anticoagulant for the prevention of venous thromboembolism and the prevention of stroke in atrial fibrillation. It is a direct factor Xa inhibitor. Apixaban has been available in Europe since May 2011. The drug was developed in a joint venture by Pfizer and Bristol-Myers Squibb. Apixaban

    ReplyDelete

All Rights Reserved by World Stroke Organization © 2017

Contact Form

Name

Email *

Message *

Powered by Blogger.